Formulations and methods for vascular permeability-related diseases or conditions
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
1. A method to decrease vascular permeability in a subject in need thereof, comprising administering a therapeutic agent to the subject at a dose of no greater than an amount equivalent to 2 mg/kg of rapamycin,
wherein the subject in need thereof has a disease or condition selected from the group consisting of blepharitis, eyelid swelling, conjunctival edema, contact lens induced conjunctivitis, pinguecula, hordeolum, and chalazion,
and the therapeutic agent is rapamycin, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the subject is a human subject.
3. The method of claim 1 , wherein the disease or condition is blepharitis.
4. The method of claim 1 , wherein the therapeutic agent is rapamycin.
5. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.5 mg/kg of rapamycin.
6. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.27 mg/kg of rapamycin.
7. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.07 mg/kg of rapamycin.
8. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.014 mg/kg of rapamycin.
9. The method of claim 1 , wherein the therapeutic agent is rapamycin, and the rapamycin is administered in a formulation containing about 2% w/w rapamycin, about 4% w/w ethanol, and about 94% w/w PEG 400.